251 related articles for article (PubMed ID: 17048976)
1. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus.
Zhao C; Vaidyanathan S; Yeh CM; Maboudian M; Armin Dieterich H
Clin Pharmacokinet; 2006; 45(11):1125-34. PubMed ID: 17048976
[TBL] [Abstract][Full Text] [Related]
2. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
3. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects.
Vaidyanathan S; Jermany J; Yeh C; Bizot MN; Camisasca R
Br J Clin Pharmacol; 2006 Dec; 62(6):690-8. PubMed ID: 17118124
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics and pharmacodynamics of aliskiren.
Vaidyanathan S; Jarugula V; Dieterich HA; Howard D; Dole WP
Clin Pharmacokinet; 2008; 47(8):515-31. PubMed ID: 18611061
[TBL] [Abstract][Full Text] [Related]
5. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor.
Buczko W; Hermanowicz JM
Pharmacol Rep; 2008; 60(5):623-31. PubMed ID: 19066408
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment.
Vaidyanathan S; Bigler H; Yeh C; Bizot MN; Dieterich HA; Howard D; Dole WP
Clin Pharmacokinet; 2007; 46(8):661-75. PubMed ID: 17655373
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
Nussberger J; Wuerzner G; Jensen C; Brunner HR
Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
[TBL] [Abstract][Full Text] [Related]
9. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects.
Limoges D; Dieterich HA; Yeh CM; Vaidyanathan S; Howard D; Dole WP
Int J Clin Pharmacol Ther; 2008 May; 46(5):252-8. PubMed ID: 18538111
[TBL] [Abstract][Full Text] [Related]
10. Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren.
Jarugula V; Yeh CM; Howard D; Bush C; Keefe DL; Dole WP
J Clin Pharmacol; 2010 Dec; 50(12):1358-66. PubMed ID: 20150520
[TBL] [Abstract][Full Text] [Related]
11. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
Fisher ND; Jan Danser AH; Nussberger J; Dole WP; Hollenberg NK
Circulation; 2008 Jun; 117(25):3199-205. PubMed ID: 18559696
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.
Vaidyanathan S; Warren V; Yeh C; Bizot MN; Dieterich HA; Dole WP
J Clin Pharmacol; 2007 Feb; 47(2):192-200. PubMed ID: 17244770
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study.
Hu P; Bartlett M; Karan RS; Jiang J; Zhang S; Zhang J; Howard D; Yeh CM; Al-Fayoumi S; Jarugula V; Dole WP
Clin Drug Investig; 2010; 30(4):221-8. PubMed ID: 20192280
[TBL] [Abstract][Full Text] [Related]
14. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.
Tapaninen T; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
J Clin Pharmacol; 2011 Mar; 51(3):359-67. PubMed ID: 20400651
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of aliskiren/hydrochlorothiazide single-pill combination tablets and free combination of aliskiren and hydrochlorothiazide.
Yan JH; Jarugula V; Sabo R; Papst CC; Zhang J; Dole WP
J Clin Pharmacol; 2012 May; 52(5):645-55. PubMed ID: 21659626
[TBL] [Abstract][Full Text] [Related]
16. Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren.
Tapaninen T; Neuvonen PJ; Niemi M
Eur J Clin Pharmacol; 2010 May; 66(5):497-502. PubMed ID: 20179914
[TBL] [Abstract][Full Text] [Related]
17. Aliskiren, the future of renin-angiotensin system blockade?
Uresin Y; Mehtar Bozkurt M; Sabirli S; Ozunal ZG
Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):835-49. PubMed ID: 17867914
[TBL] [Abstract][Full Text] [Related]
18. Maximum renal responses to renin inhibition in healthy study participants: VTP-27999 versus aliskiren.
Barkoudah E; van Thiel BS; Fisher ND; Gregg RA; Danser AH; Moukarbel GV; Hollenberg NK
J Hypertens; 2016 May; 34(5):935-41. PubMed ID: 26882043
[TBL] [Abstract][Full Text] [Related]
19. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
